Adverse events1,338

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,338

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	ANAEMIA	Blood and lymphatic system disorders	Ipilimubab+Paclitaxel/Carboplatin (Concurrent) NSCLC	22	71
other	ANAEMIA	Blood and lymphatic system disorders	Placebo/Ipilimumab+ Paclitaxel/Carboplatin (Sequential) NSCLC	15	67
other	ANAEMIA	Blood and lymphatic system disorders	Placebo + Paclitaxel/Carboplatin NSCLC	19	65
other	ANAEMIA	Blood and lymphatic system disorders	Ipilimumab/Placebo + Paclitaxil/Carboplatin (Concurrent) SCLC	13	42
other	ANAEMIA	Blood and lymphatic system disorders	Placebo/Ipilimumab + Paclitaxel/Carboplatin (Sequential) SCLC	12	42
other	ANAEMIA	Blood and lymphatic system disorders	Placebo + Paclitaxel/Carboplatin SCLC	10	44
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Ipilimubab+Paclitaxel/Carboplatin (Concurrent) NSCLC	18	71
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Placebo/Ipilimumab+ Paclitaxel/Carboplatin (Sequential) NSCLC	11	67
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Placebo + Paclitaxel/Carboplatin NSCLC	10	65
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Ipilimumab/Placebo + Paclitaxil/Carboplatin (Concurrent) SCLC	13	42
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Placebo/Ipilimumab + Paclitaxel/Carboplatin (Sequential) SCLC	23	42
other	ARTHRALGIA	Musculoskeletal and connective tissue disorders	Placebo + Paclitaxel/Carboplatin SCLC	15	44
other	DIZZINESS	Nervous system disorders	Ipilimubab+Paclitaxel/Carboplatin (Concurrent) NSCLC	9	71
other	DIZZINESS	Nervous system disorders	Placebo/Ipilimumab+ Paclitaxel/Carboplatin (Sequential) NSCLC	7	67
other	DIZZINESS	Nervous system disorders	Placebo + Paclitaxel/Carboplatin NSCLC	5	65
other	DIZZINESS	Nervous system disorders	Ipilimumab/Placebo + Paclitaxil/Carboplatin (Concurrent) SCLC	1	42
other	DIZZINESS	Nervous system disorders	Placebo/Ipilimumab + Paclitaxel/Carboplatin (Sequential) SCLC	2	42
other	DIZZINESS	Nervous system disorders	Placebo + Paclitaxel/Carboplatin SCLC	2	44
other	HYPOXIA	Respiratory, thoracic and mediastinal disorders	Ipilimubab+Paclitaxel/Carboplatin (Concurrent) NSCLC	5	71
other	HYPOXIA	Respiratory, thoracic and mediastinal disorders	Placebo/Ipilimumab+ Paclitaxel/Carboplatin (Sequential) NSCLC	1	67

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00527735/events

API reference For AI assistants

Adverse events1,338

Sources 3

Read this list from software.